Equities

Rocket Pharmaceuticals Inc

  • Add to watchlist
  • Add to portfolio

Rocket Pharmaceuticals Inc

Actions
  • Price (EUR)2.50
  • Today's Change0.102 / 4.25%
  • Shares traded7.61k
  • 1 Year change-86.89%
  • Beta0.6128
Data delayed at least 15 minutes, as of Jul 08 2025.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company focused on the development of gene therapies for rare and devastating diseases. The Company has two clinical stage and one pre-clinical stage in vivo adeno-associated viral (AAV) programs in the United States, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is the most common form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart resulting in enlarged heart chambers that are unable to pump blood.

  • Revenue in USD (TTM)0.00
  • Net income in USD-258.03m
  • Incorporated1999
  • Employees299.00
  • Location
    Rocket Pharmaceuticals Inc9 Cedarbrook DriveCRANBURY 08512United StatesUSA
  • Phone+1 (646) 440-9100
  • Fax+1 (781) 676-2155
  • Websitehttps://www.rocketpharma.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.